Efficacy of Atorvastatin Plus Pegylated Interferon and Ribavirin Versus Pegylated Interferon and Ribavirin Alone in Chronic Hepatitis C Patients with Genotype-3a
Journal Title: Pakistan Biomedical Journal - Year 2019, Vol 2, Issue 1
Abstract
Chronic hepatitis C infection has created a huge burden of disease causing serious health effects. The combination therapy used to treat hepatitis C virus (HCV) infection includes Pegylated interferon and Ribavirin. As cholesterol biosynthesis plays a pivotal role in HCV replication, the use of various statins has been associated with higher sustained viral response. Objective: To compare the efficacy of atorvastatin plus pegylated interferon and ribavirin versus pegylated interferon and ribavirin alone in patients of chronic hepatitis C with genotype-3a Methods: This Randomized controlled trial was conducted at outpatient department, Mayo Hospital Lahore for six months i.e. May to November 2017. After ethical approval, 60 patients of ages 25 to 55 years of either gender with chronic hepatitis C with genotype 3a were included in the study. Informed consent was taken from all patients. Then patients were randomly allocated into two groups “A” and “B” using random number table. Patients in Group A received standard of care treatment for chronic hepatitis C i.e. pegylated interferon and ribavirin while the patients in Group B also received tab atorvastatin along with the standard treatment. Patients were follow up for 4 week. Blood samples were collected and HCV RNA detection. All this information were entered in proforma Results: In standard therapy group, the mean age of patients was 39.50±8.39years. In atorvastatin plus standard therapy group, the mean age of patients was 34.30±6.78years. In standard therapy group, there were 25 (83.3%) males and 5 (16.7%) females. In atorvastatin plus standard therapy group, there were 16 (53.3%) males and 14 (46.7%) females. After 4 weeks, Rapid Virological Response (RVR) was achieved in 4 (13.3%) patients in standard therapy group while in 14 (46.7%) in atorvastatin plus standard therapy group. The difference was significant (p<0.05) Conclusions: Atorvastatin in combination with Pegylated interferon and ribavirin have better efficacy as compared to Pegylated interferon & ribavirin alone in chronic hepatitis C-3a.
Authors and Affiliations
Waqas Gulzar1, Zafar Niaz2*, Sami Ullah Mumtaz2, Somia Iqtadar2, Tayyeba Komal3 and Sajid Abaidullah2
Keywords
Related Articles
- EP ID EP694173
- DOI https://doi.org/10.52229/pbmj.v2i1.28
- Views 194
- Downloads 0
Human Papilloma Virus as one of the etiological factor for oral Squamous Cell Carcinoma-an Updated Review
Human papilloma virus (HPV) related head and neck squamous cell cancer (HNSCC) has varying etiology, genetic as well as environmental factors involved and differential clinicicopathological features. HNSCC came in the li...
Effect of Storage on Physio-Chemical Properties of Peanut Yogurt
Peanuts may be consumed in a variety of processed forms like roasted, raw and processed etc. and represent as a multimillion dollar crop worldwide with many potential dietary benefits as it contains high protein and heal...
Immunological memory as the fundamentals of vaccines
The immune system also called as the defense system involves many different cells that work as soldiers in an individual. These immune cells provide protection against various pathogens. For better protection of an indiv...
Dietary Options in Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) is the disease condition in which our gastrointestinal (GI) tract is affected and cause abdominal pain and discomfort that is associated with change in the stools form and frequency. In thi...
Signicance of Philadelphia Chromosome in Chronic Myeloid Leukemia Patients of Anmol Hospital, Lahore, Pakistan
Chronic myelogenous Leukemia is (Clonal stem cell disorder) cancer which starts in bone marrow a soft tissue inside bones that aids to form blood cells. It is rst form of cancer that was rstly recognize to associate stro...